Loading…
Loading…
HLOSF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HLOSF and 80,000+ other tickers.
See exactly how HLOSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HLOSF and 80,000+ other tickers.
Healios K.K. is a biotechnology firm specializing in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products, with operations spanning Japan, Europe, and the United States. The company's robust pipeline features several advanced cellular and tissue-based therapies: iPSC-derived regenerative medicines HLCR011 and HLCR012, which target age-related macular degeneration; HLCL041, an iPSC regenerative medicine for metabolic liver disease; HLCM051, a regenerative treatment for ischemic stroke and acute respiratory distress syndrome; and…
No recent news available.